secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2026-02-10T23:59:59+00:00
Accession:  0000939767-26-000019
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis Q4 revenue $599M, diluted EPS $0.88; cabozantinib franchise up 17% in FY2025
--------------------------------------------------------------------------------

- Q4 2025 total revenue $598.7M vs $566.8M YoY; GAAP diluted EPS $0.88 vs $0.48.
- FY2025 net product revenue $2.123B, up from $1.809B, driven by cabozantinib volume growth.
- GAAP net income $782.6M in FY2025 ($2.78 diluted EPS); non-GAAP $869.5M ($3.08 diluted EPS).
- R&D expenses fell to $825M (down 9.4% YoY); SG&A rose 5.4% to $518.7M.
- NDA for zanzalintinib in mCRC accepted; STELLAR-303/304 readouts and trials expected in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976726000019/0000939767-26-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976726000019/exel-20260210.htm
  HTML page:      https://secwatch.observer/filing/0000939767-26-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer